Analysis Group Team’s Research Comparing Clinical Trial Outcomes with Real-World External Controls in Chronic Kidney Disease Wins Poster Award at European Society of Endocrinology Meeting
August 18, 2021
Patients with chronic hypoparathyroidism (CH), a rare condition characterized by low levels of calcium and parathyroid hormone, are known to be at higher risk of developing renal complications, including chronic kidney disease (CKD). An Analysis Group team partnered with colleagues from Takeda, Albany Medical College, and Aarhus University to study whether treatment with recombinant human parathyroid hormone (1-84) (rhPTH(1-84)) could reduce the likelihood of developing CKD.
The team, which included Vice President Elyse Swallow and Manager Fan Mu, compared the five-year CKD outcomes of a cohort of CH patients treated with rhPTH(1-84) in clinical trials versus a control group constructed from a large database of electronic medical records, using similar inclusion and exclusion criteria as the clinical trial cohort. They found that after adjusting for baseline differences, CH patients treated with rhPTH(1-84) were significantly less likely to develop CKD compared with the control cohort.
A poster presentation of the team’s work was named one of the top four clinical posters at the 2021 European Congress of Endocrinology.